“In the investing blog, I seek to help you take sound investment decisions free from emotion by sharing my objective insights on markets, sectors, and companies.”
July has been a good month for biotech investors. Share prices in the biotech sector as measured by the NYSE Biotechnology Index are up 24% compared to the 6.6% gain for the S&P 500. Earlier in the month, Amgen (AMGN) reported better-than-expected results from a trial of its experimental bone-protecting drug denosumab in patients with advanced breast cancer.… Read More »
Biotechnology, which has been on a roll, declined after the much-anticipated American Society of Clinical Oncologists meeting in early June in New Orleans, where cancer specialists deliberated on the merits of new treatments. The two extant ETFs which focus on this industry are iShares Nasdaq Biotechnology (AMEX:IBB) and Biotech HOLDRs (AMEX:BBH). Before deciding to dump or load up… Read More »
Investing in biotech stocks has never been for the faint-hearted as many biotech companies have high cash burn rates. The biotech industry however has a few things going for it. Read on to learn more about investment opportunities in this industry. Shares of biotechnology companies have declined, after the much anticipated American Society of Clinical Oncologists meeting in… Read More »
The favorable dynamics for the Biotechnology industry is attracting investor attention. On the heels of recent gains, there are reasons to be optimistic on continued out-performance. An efficient Food and Drug Administration, progress on extension of new products, trouble in ‘major pharma’ land and reasonable valuation create a favorable milieu for investing in the biotechnology sector. These conditions… Read More »
The Fidelity and ETF Core and Focus model portfolios have gained at annualized rates of 14.4% and 17.4%, respectively since 1994. The model portfolios will be repositioned with new mutual fund and ETF recommendations on Friday, March 31. Learn more about AlphaProfit's Free and Premium Service investment newsletters.
THE GOOD NEWS JUST BEGINS!
DEC. 1993 to DEC. 2022| Fidelity Agg. Growth | 17.5% |
| Fidelity Growth | 14.4% |
| ETF Agg. Growth | 17.4% |
| ETF Growth | 14.2% |
| No-Fee Growth (inc. 2009) | 10.7% |
| S&P 500 | 9.6% |
DEC. 2013 to DEC. 2022| Win Rate | 91% |
| Avg. Holding Period | 2.6 months |
| Avg. Gain | 12.6% |
